6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors were tested for these tumors in clinical trials. In a screen for novel drugs that selectively...

Full description

Bibliographic Details
Main Authors:	Issaeva, N, Thomas, H, Djureinovic, T, Djurenovic, T, Jaspers, J, Stoimenov, I, Kyle, S, Pedley, N, Gottipati, P, Zur, R, Sleeth, K, Chatzakos, V, Mulligan, E, Lundin, C, Gubanova, E, Kersbergen, A, Harris, A, Sharma, R, Rottenberg, S, Curtin, N, Helleday, T
Format:	Journal article
Language:	English
Published:	2010

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

Similar Items